CID4 Co-Founder and CSO, Rick Duke, Ph.D. attended the 13th Annual C21 BioVentures Forum on May 24-26 in Napa, CA, along with management of CID4 portfolio companies PeptiVir and VetDC. CID4’s goals for attending C21, one of the premier early-stage life science partnering meetings, were three-fold:
- First, to introduce the CID4 concept to the biotechnology, pharmaceutical and life science investor communities
- Second, to introduce CID4’s current portfolio companies, as well as companies and inventors who submitted information to the CID4 Innovation Database (submit your company and/or technology information HERE), to potential partners, licensees and investors, and
- Third, to interact with other organizations with similar goals as CID4 to determine best practices for technology selection and institute funding.
CID4 and Portfolio Companies held meetings with the following organizations:
- Venture capital: SV Life Sciences, Vivo Ventures, MedImmune Ventures, Bay City Capital, Kleiner Perkins Caulfield and Byers, BDC Venture Capital, Novo Ventures, Skyline Ventures, CDBI Capital, MP Healthcare Venture Management, Canaan Partners and Woodside Partners;
- Industry partners: AstraZeneca, Genentech, Bayer, Takeda, Merck, Debiopharm, Pfizer, Novartis, Abbott, Merck, Teva and Onyx; and
- Others: Silicon Valley Bank, Royal Bank of Canada, Aquilo Partners, CTI, New Biology Partners and Finox.
PeptiVir was represented at the Forum by co-founde Robert Hodges, Ph.D. (VP of Chemistry) and Kathryn Holmes, Ph.D. (VP of Virology), while VetDC was represented by President and CEO Steven Roy who said,“C21 BioVentures is one of the premier events in the country in terms of providing access to highly influential members of the life science investment community. Not only was VetDC able to gain valuable exposure as a presenting company but the conference format provided ample opportunities for formal and informal networking with investors and potential partners, yielding over 25 contacts for further follow-up. CID4's presence proved to be invaluable, both in terms of sharing the VetDC story as well as raising the awareness of Colorado Bioscience. In fact, many attendees mentioned that they were surprised to see so many Colorado companies represented at the conference.”
Overall it was great experience for the Colorado contingency, which also included KromaTiD and Vidasym who were represented by Terry Opgenorth, Ph.D., and demonstrated the value of CID4 enabling industry and investors to reach into technology-rich Colorado for the best in pre-clinical and clinical stage technologies and companies.
Comments